Literature DB >> 10390008

Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer.

A S Protheroe1, R E Banks, M Mzimba, W H Porter, J Southgate, P N Singh, M Bosomworth, P Harnden, P H Smith, P Whelan, P J Selby.   

Abstract

Reduced expression of the adhesion molecule E-cadherin has been associated with increased invasiveness and poorer survival in patients with bladder cancer. We have examined soluble E-cadherin (sE-cadherin) and total protein concentrations in urine from patients with bladder cancer (n = 34), non-neoplastic benign urological diseases (n = 14) and healthy controls (n = 21) to determine their diagnostic and prognostic significance. Soluble E-cadherin concentrations of the cancer group were significantly higher (P < 0.001) than those of the controls but the benign group was not significantly different from either the cancer group or the controls. When sE-cadherin concentrations were adjusted for creatinine, similar but more statistically significant results were obtained and the benign group was significantly elevated compared with the controls (P < 0.01). No differences were apparent between the invasive (pT1-4) and non-invasive (pTa) cancers. Urinary total protein concentrations in the cancer group were significantly higher than the controls (P < 0.001) and the benign group (P < 0.05) although no difference was seen between the benign group and patients with non-invasive (pTa) cancer or between the benign group and controls. When expressed as the protein/creatinine index, results were similar but more statistically significant and a significant difference was seen between invasive and non-invasive cancers (P < 0.01). Only the protein/creatinine index correlated significantly with stage of the tumour (P < 0.01). It is concluded that urinary sE-cadherin measurements are of no greater value than urinary total protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390008      PMCID: PMC2363021          DOI: 10.1038/sj.bjc.6690351

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

1.  Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas.

Authors:  K F Becker; H Höfler
Journal:  J Natl Cancer Inst       Date:  1995-07-19       Impact factor: 13.506

2.  Soluble forms of the adhesion molecule E-cadherin in urine.

Authors:  R E Banks; W H Porter; P Whelan; P H Smith; P J Selby
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

3.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.

Authors:  K Yoshiura; Y Kanai; A Ochiai; Y Shimoyama; T Sugimura; S Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

4.  The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice.

Authors:  J Reading; R R Hall; M K Parmar
Journal:  Br J Urol       Date:  1995-05

5.  Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer.

Authors:  P K Lipponen; M J Eskelinen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Molecular detection of primary bladder cancer by microsatellite analysis.

Authors:  L Mao; M P Schoenberg; M Scicchitano; Y S Erozan; A Merlo; D Schwab; D Sidransky
Journal:  Science       Date:  1996-02-02       Impact factor: 47.728

7.  E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival.

Authors:  K N Syrigos; T Krausz; J Waxman; H Pandha; G Rowlinson-Busza; J Verne; A A Epenetos; M Pignatelli
Journal:  Int J Cancer       Date:  1995-12-20       Impact factor: 7.396

8.  Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.

Authors:  M A D'Hallewin; L Baert
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

9.  E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.

Authors:  J S Ross; A D del Rosario; H L Figge; C Sheehan; H A Fisher; H X Bui
Journal:  Hum Pathol       Date:  1995-09       Impact factor: 3.466

10.  Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence.

Authors:  T R Griffiths; I Brotherick; R I Bishop; M D White; D M McKenna; C H Horne; B K Shenton; D E Neal; J K Mellon
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  10 in total

1.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.

Authors:  A Vlahou; P F Schellhammer; S Mendrinos; K Patel; F I Kondylis; L Gong; S Nasim; G L Wright
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  E-cadherin gene 3'-UTR C/T polymorphism in Turkish patients with nephrolithiasis.

Authors:  Akin Yilmaz; Sevda Menevse; Metin Onaran; Ilker Sen; Mehmet Ali Ergun; Ahmet Camtosun; Bora Kupeli; Ibrahim Bozkirli
Journal:  Mol Biol Rep       Date:  2010-12-14       Impact factor: 2.316

3.  Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer.

Authors:  M Helal Uddin Biswas; Cheng Du; Chuanyou Zhang; Juerg Straubhaar; Lucia R Languino; K C Balaji
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

Review 4.  Soluble cadherins as cancer biomarkers.

Authors:  Olivier De Wever; Lara Derycke; An Hendrix; Gert De Meerleer; François Godeau; Herman Depypere; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

Review 5.  Soluble E-cadherin: more than a symptom of disease.

Authors:  Magdalena M Grabowska; Mark L Day
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

6.  Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.

Authors:  R Kuefer; M D Hofer; C S M Zorn; O Engel; B G Volkmer; M A Juarez-Brito; M Eggel; J E Gschwend; M A Rubin; M L Day
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

Review 7.  Levels of soluble E-cadherin in breast, gastric, and colorectal cancers.

Authors:  Ombretta Repetto; Paolo De Paoli; Valli De Re; Vincenzo Canzonieri; Renato Cannizzaro
Journal:  Biomed Res Int       Date:  2014-09-16       Impact factor: 3.411

8.  Pentapartite fractionation of particles in oral fluids by differential centrifugation.

Authors:  Chiho Hiraga; Satoshi Yamamoto; Sadamitsu Hashimoto; Masataka Kasahara; Tamiko Minamisawa; Sachiko Matsumura; Akira Katakura; Yasutomo Yajima; Takeshi Nomura; Kiyotaka Shiba
Journal:  Sci Rep       Date:  2021-02-08       Impact factor: 4.379

Review 9.  Cleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis.

Authors:  Porfirio Nava; Ryuta Kamekura; Asma Nusrat
Journal:  Tissue Barriers       Date:  2013-04-01

10.  CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate Cancer.

Authors:  Zhenkun Ma; Ye Gao; Wei Liu; Long Zheng; Ben Jin; Bei Duan; Hongjun Xie; Peng Guo; Jin Zeng; Ke Wang; Shan Xu; Xinyang Wang; Dalin He; Lei Li
Journal:  Dis Markers       Date:  2020-11-01       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.